
Opinion|Videos|September 20, 2024
Future Direction of Intravenous and Subcutaneous Biologics
Author(s)Jennifer Seminerio, MD
Dr. Seminerio predicts how the future landscape will change for intravenous and subcutaneous biologics.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Do you foresee IV and subQ route of administration always having a role moving forward? How do you see the treatment landscape changing?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
3
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
4
Recent COVID vaccination cuts household transmission by half
5





















